Online citations, reference lists, and bibliographies.
← Back to Search

Actions Of The FAAH Inhibitor URB597 In Neuropathic And Inflammatory Chronic Pain Models

A. Jayamanne, Ruth Greenwood, V. Mitchell, S. Aslan, D. Piomelli, C. Vaughan
Published 2006 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
While cannabinoid receptor agonists have analgesic activity in chronic pain states, they produce a spectrum of central CB1 receptor‐mediated motor and psychotropic side effects. The actions of endocannabinoids, such as anandamide are terminated by removal from the extracellular space, then subsequent enzymatic degradation by fatty‐acid amide hydrolase (FAAH). In the present study, we compared the effect of a selective FAAH inhibitor, URB597, to that of a pan‐cannabinoid receptor agonist HU210 in rat models of chronic inflammatory and neuropathic pain. Systemic administration of URB597 (0.3 mg kg−1) and HU210 (0.03 mg kg−1) both reduced the mechanical allodynia and thermal hyperalgesia in the CFA model of inflammatory pain. In contrast, HU210, but not URB597, reduced mechanical allodynia in the partial sciatic nerve‐ligation model of neuropathic pain. HU210, but not URB597, produced a reduction in motor performance in unoperated rats. The effects of URB597 in the CFA model were dose dependent and were reduced by coadministration with the cannabinoid CB1 antagonist AM251 (1 mg kg−1), or the CB2 and SR144528 (1 mg kg−1). Coadministration with AM251 plus SR144528 completely reversed the effects of URB597. These findings suggest that the FAAH inhibitor URB597 produces cannabinoid CB1 and CB2 receptor‐mediated analgesia in inflammatory pain states, without causing the undesirable side effects associated with cannabinoid receptor activation.
This paper references
Isolation and structure of a brain constituent that binds to the cannabinoid receptor.
W. Devane (1992)
2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain.
T. Sugiura (1995)
Jayamanne et al Actions of FAAH inhibition in chronic pain states
Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities.
D. Compton (1993)
Pain modulation by release of the endogenous cannabinoid anandamide.
J. M. Walker (1999)
Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain.
I. Adams (1998)
Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide.
D. Boger (2000)
A structure-activity relationship study on N-arachidonoyl-amino acids as possible endogenous inhibitors of fatty acid amide hydrolase.
Maria Grazia Cascio (2004)
Hypoactivity of the Spinal Cannabinoid System Results in NMDA-Dependent Hyperalgesia
J. D. Richardson (1998)
Carrier‐mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2‐arachidonylglycerol
M. Beltramo (2000)
Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent.
E. Fride (1993)
Control of pain initiation by endogenous cannabinoids
A. Calignano (1998)
An endocannabinoid mechanism for stress-induced analgesia
A. Hohmann (2005)
Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase
B. Cravatt (2001)
Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes.
S. Saario (2004)
The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications.
D. Lambert (2005)
Pharmacological actions of cannabinoids.
R. Pertwee (2005)
The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain
S. Jaggar (1998)
The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity.
D. Compton (1997)
Evidence that CB1 and CB2 cannabinoid receptors mediate antinociception in neuropathic
D. A. SCOTT (2004)
The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice.
P. B. Smith (1994)
Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity
N. Strangman (1998)
The VR1 Antagonist Capsazepine Reverses Mechanical Hyperalgesia in Models of Inflammatory and Neuropathic Pain
K. Walker (2003)
The synthetic cannabinoid WIN55,212‐2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain
D. Bridges (2001)
VR1, but not P2X3, increases in the spared L4 DRG in rats with L5 spinal nerve ligation
T. Fukuoka (2002)
The Rat
H. Harris (1958)
Cellular accumulation of anandamide: consensus and controversy
C. Hillard (2003)
CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain
N. Clayton (2002)
Enzymes of porcine brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptors.
S. Goparaju (1999)
Identification of a New Class of Molecules, the Arachidonyl Amino Acids, and Characterization of One Member That Inhibits Pain*
S. Huang (2001)
Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat
D. Scott (2004)
Modulation of anxiety through blockade of anandamide hydrolysis
S. Kathuria (2003)
Brain monoglyceride lipase participating in endocannabinoid inactivation
T. V. Dinh (2002)
disorders produced in rats by partial sciatic nerve injury
A. SIEGLING (2001)
Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid
M. BELTRAMO (2000)
Reversible Inhibitors of Fatty Acid Amide Hydrolase That Promote Analgesia: Evidence for an Unprecedented Combination of Potency and Selectivity
A. Lichtman (2004)
The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain
A. Fox (2001)
The analgesic effects of R(+)-WIN 55,212–2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain
U. Herzberg (1997)
Functional disassociation of the central and peripheral fatty acid amide signaling systems.
B. Cravatt (2004)
Spinal cannabinoids are anti-allodynic in rats with persistent inflammation
W. Martin (1999)
A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia
K. Hargreaves (1988)
Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors
J. D. Richardson (1998)
Quantitative assessment of tactile allodynia in the rat paw
S. Chaplan (1994)
Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia
A. Lichtman (2004)
Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats
G. Lim (2003)
Characterization of Δ9-Tetrahydrocannabinol and Anandamide Antinociception in Nonarthritic and Arthritic Rats
F. Smith (1998)
Lack of involvement of capsaicin-sensitive primary afferents in nerve-ligation injury induced tactile allodynia in rats
M. Ossipov (1999)
HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor.
L. Hanuš (1999)
A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury
Z. Seltzer (1990)
3-[2-Cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): A Novel Cannabinoid CB1/CB2 Receptor Partial Agonist with Antihyperalgesic and Antiallodynic Effects
J. de Vry (2004)
Peripheral capsaicin receptors increase in the inflamed rat hindpaw: a possible mechanism for peripheral sensitization
S. Carlton (2001)
Inhibitors of fatty acid amide hydrolase reduce carrageenan‐induced hind paw inflammation in pentobarbital‐treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors
S. Holt (2005)
A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain
L. Kehl (2003)
CB2 cannabinoid receptor-mediated peripheral antinociception
T. Malan (2001)
A-425619 [1-Isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a Novel Transient Receptor Potential Type V1 Receptor Antagonist, Relieves Pathophysiological Pain Associated with Inflammation and Tissue Injury in Rats
P. Honore (2005)
Impaired nociception and pain sensation in mice lacking the capsaicin receptor.
M. Caterina (2000)
Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS
M. Ibrahim (2003)
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
B. Cravatt (1996)
Anandamide amidohydrolase reacting with 2‐arachidonoylglycerol, another cannabinoid receptor ligand
S. Goparaju (1998)
Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat.
P. Beaulieu1 (2000)
Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry
K. Tsou (1998)
Repeated treatment with the synthetic cannabinoid WIN 55,212‐2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain
B. Costa (2004)
Cannabinoid CB1 receptor upregulation in a rat model of chronic neuropathic pain
A. Siegling (2001)

This paper is referenced by
Cannabinoids as pharmacotherapies for neuropathic pain: From the bench to the bedside
E. Rahn (2011)
Endocannabinoids in the retina: From marijuana to neuroprotection
S. Yazulla (2008)
Delay Discounting and Cannabinoid Enzyme Inhibitors
Devin Andrew Galdieri (2018)
Cannabinoid Modulation of the Behavioral Effects of Morphine
Laurence L. Miller (2010)
Current evidence of cannabinoid‐based analgesia obtained in preclinical and human experimental settings
J. Lötsch (2018)
The potency of the fatty acid amide hydrolase inhibitor URB597 is dependent upon the assay pH.
Ben Paylor (2006)
Effects of Fatty Acid Amide Hydrolase Inhibitors Acute Administration on the Positive and Cognitive Symptoms of Schizophrenia in Mice
M. Kruk-Slomka (2019)
Modulation of the anti‐nociceptive effects of 2‐arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model
J. Desroches (2008)
Encapsulation of cannabinoid drugs in nanostructured lipid carriers.
E. Esposito (2016)
Analgesic effects of FAAH inhibitor in the insular cortex of nerve-injured rats
Min Jee Kim (2018)
Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain
M. Jhaveri (2007)
Localization of the Endocannabinoid-Degrading Enzyme Fatty Acid Amide Hydrolase in Rat Dorsal Root Ganglion Cells and Its Regulation after Peripheral Nerve Injury
I. Lever (2009)
Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice
S. Kinsey (2011)
Inhibition of Fatty Acid Amide Hydrolase: A Potential Treatment for Neuropathic Pain
T. Trang (2007)
quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors : Modulation at the N-portion of biphenyl-3-yl alkylcarbamates Permalink
M. Mor (2013)
Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain
M. Jhaveri (2008)
The fatty acid amide hydrolase 385 A/A (P129T) variant: haplotype analysis of an ancient missense mutation and validation of risk for drug addiction
Jonathan M. Flanagan (2006)
Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit
Richard A. Slivicki (2018)
AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain
B. Costa (2006)
Activation of TRPA1 Channels by the Fatty Acid Amide Hydrolase Inhibitor 3′-Carbamoylbiphenyl-3-yl cyclohexylcarbamate (URB597)
W. Niforatos (2007)
Therapeutic potential of endocannabinoid-hydrolysing enzyme inhibitors.
S. Saario (2007)
From endocannabinoid profiling to 'endocannabinoid therapeutics'.
A. Ligresti (2009)
M. Kianian (2012)
Conference on ‘ PUFA mediators : implications for human health ’ Symposium 3 : Cannabinoids in human health Endocannabinoid system and pain : an introduction
J. Burston (2014)
Full Fatty Acid Amide Hydrolase Inhibition Combined with Partial Monoacylglycerol Lipase Inhibition: Augmented and Sustained Antinociceptive Effects with Reduced Cannabimimetic Side Effects in Mice
Sudeshna Ghosh (2015)
The synthesis and biological evaluation of para-substituted phenolic N-alkyl carbamates as endocannabinoid hydrolyzing enzyme inhibitors.
Anna Minkkilae (2009)
Attenuation of serotonin-induced itch responses by inhibition of endocannabinoid degradative enzymes, fatty acid amide hydrolase and monoacylglycerol lipase
Nurcan Calimli Tosun (2014)
Synthesis and Preclinical Evaluation of [18F]FCHC for Neuroimaging of Fatty Acid Amide Hydrolase
T. Shoup (2014)
Cannabinoids and Motor Control of the Basal Ganglia: Therapeutic Potential in Movement Disorders
T. Morera-Herreras (2016)
Development of an AmpliSeqTM Panel for Next-Generation Sequencing of a Set of Genetic Predictors of Persisting Pain
D. Kringel (2018)
A perspective review on fatty acid amide hydrolase (FAAH) inhibitors as potential therapeutic agents.
R. K. P. Tripathi (2019)
The fatty acid amide hydrolase (FAAH) inhibitor PF‐3845 acts in the nervous system to reverse LPS‐induced tactile allodynia in mice
L. Booker (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar